The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)
Abstract
Nonclinical testing of human pharmaceuticals is conducted to assess the safety of compounds to be studied in human clinical trials and for marketing of new drugs. Although there is no exact number and type of nonclinical studies required for safety assessments, as there is inherent flexibility for each new compound, the traditional approach is outlined in various FDA and ICH guidance documents and involves a combination of in vitro assays and whole animal testing methods. Recent advances in science have led to the emergence of numerous new approach methodologies (NAMs) for nonclinical testing that are currently being used in various aspects of drug development. Traditional nonclinical testing methods can predict clinical outcomes, although improvements in these methods that can increase predictivity of clinical outcomes are encouraged and needed. This paper discusses FDA/CDER's view on the opportunities and challenges of using NAMs in drug development especially for regulatory purposes, and also includes examples where NAMs are currently being used in nonclinical safety assessments and where they may supplement and/or enhance current testing methods. FDA/CDER also encourages communication with stakeholders regarding NAMs and is committed to exploring the use of NAMs to improve regulatory efficiency and potentially expedite drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 2×
“In recent years, the development of 2D cell cultures and 3D brain organoids derived from human induced pluripotent stem cells (iPSC) of patients with various neurological or psychiatric disorders have been used to enhance the understanding of relevant connections between genetics, physiology, other individual risk var…”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
The use of brain organoids to investigate neural development and disease
Di Lullo, E., & Kriegstein, A. R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.107 · Cited by 788
Building Models of Brain Disorders with Three-Dimensional Organoids
Amin, N. D., & Paşca, S. P. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.007 · Cited by 312
The promises and challenges of human brain organoids as models of neuropsychiatric disease
Quadrato, G., Brown, J., & Arlotta, P. (2016) · Nature Medicine · doi:10.1038/nm.4214 · Cited by 304
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
The future of drug safety testing: expanding the view and narrowing the focus
Stevens, J. L., & Baker, T. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.009 · Cited by 286
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
Mead, A. N., Amouzadeh, H. R., Chapman, K., Ewart, L., Giarola, A., Jackson, S. J., Jarvis, P., Jordaan, P., Redfern, W., Traebert, M., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.05.002 · Cited by 67
Prediction of clinical risks by analysis of preclinical and clinical adverse events
Clark, M. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.02.008 · Cited by 36
Cited by
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Towards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Current opinion on risk assessment of cosmetics
Kim, K.-B., Kwack, S. J., Lee, J. Y., Kacew, S., & Lee, B.-M. (2021) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2021.1907264 · Cited by 63
“In the cosmetics industry outside of Europe, the need for newapproach methodologies (NAMs) to identify hazardous cosmetics or cosmetic ingredients was also deemed inevitable (Andersen et al. 2019; Avila et al. 2020; Chen et al. 2020b; Punt et al. 2020).”
BackgroundCarratt, S. A., Zuch de Zafra, C. L., Oziolor, E., Rana, P., Vansell, N. R., Mangipudy, R., & Vaidya, V. S. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfae122 · Cited by 59
Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium
Rusyn, I., Sakolish, C., Kato, Y., Stephan, C., Vergara, L., Hewitt, P., Bhaskaran, V., Davis, M., Hardwick, R. N., Ferguson, S. S., et al. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac061 · Cited by 43
Metadata
- Authors
- Avila, A. M., Bebenek, I., Bonzo, J. A., Bourcier, T., Davis Bruno, K. L., Carlson, D. B., Dubinion, J., Elayan, I., Harrouk, W., Lee, S.-L., Mendrick, D. L., Merrill, J. C., Peretz, J., Place, E., Saulnier, M., Wange, R. L., Yao, J., Zhao, D., & Brown, P. C.
- Venue
- Regulatory Toxicology and Pharmacology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 114
- Pages
- 104662
- ISSN
- 0273-2300 (ISSN-L)
- OpenAlex
- W3017834715
- Cited by
- 196
- References
- 12
- FWCI
- 20.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). https://app.cochat.ai/papers/10.1016/j.yrtph.2020.104662
- The paper
- Avila, A. M., Bebenek, I., Bonzo, J. A., Bourcier, T., Davis Bruno, K. L., Carlson, D. B., Dubinion, J., Elayan, I., Harrouk, W., Lee, S.-L., Mendrick, D. L., Merrill, J. C., Peretz, J., Place, E., Saulnier, M., Wange, R. L., Yao, J., Zhao, D., & Brown, P. C. (2020). An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2020.104662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.